Plain-English translation of NCT05687851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called cadonilimab (also known as AK104) paired with radiation therapy to treat locally advanced cervical cancer. Cadonilimab is an immune-boosting drug designed to help your body's own immune system fight cancer. The study is for women who cannot tolerate standard chemotherapy but still need treatment for their cancer.
Most women with locally advanced cervical cancer are treated with chemotherapy combined with radiation, but some patients cannot tolerate chemotherapy due to severe side effects. This trial exists to see if the medication alone, combined with radiation therapy, can be an effective alternative for patients in that situation.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion every 3 weeks while undergoing radiation therapy to your pelvis and cervix. Treatment continues for up to 2 years or until your cancer improves, side effects become too severe, or you and your doctor decide to stop. You would have regular clinic visits to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China